Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,619.50
Bid: 1,619.00
Ask: 1,619.50
Change: -147.00 (-8.32%)
Spread: 0.50 (0.031%)
Open: 1,616.50
High: 1,621.00
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

Wed, 01st May 2024 07:46

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

The Fed announces its latest interest rate decision at 1900 BST. It is expected to keep rates on hold this week, with Chair Jerome Powell likely to say that the central bank is not yet confident enough to cut as inflation remains lofty.

Powell is expected to sound hawkish in a subsequent press conference following the decision.

"With the markets so bearishly positioned, there's a chance stocks could surge higher on Wednesday if the Fed sticks to their steady state, more so if investors are prepared to engage in a 'buy-the-fact' dynamic when Powell takes centre stage," SPI Asset Management analyst Stephen Innes commented.

"While risks around the Fed's mandate may appear more balanced now compared to the peak of the inflation scare, recent core price growth readings emphasize that inflation remains a primary concern, overshadowing worries about other economic indicators, so there is room for hawks to fly."

In early UK corporate news, GSK lifted its outlook, while Haleon affirmed guidance. Next said its first-quarter went better than planned, but expects a "weaker" second-quarter.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up slightly at 8,146.13

----------

Hang Seng: financial markets in Hong Kong closed

Nikkei 225: down 0.3% at 38,274.05

S&P/ASX 200: down 1.2% at 7,569.90

----------

Dow: closed down 570.17 points, 1.5%, at 37,815.92

S&P 500: closed down 1.6% at 5,035.69

Nasdaq Composite: closed down 2.0% at 15,657.82

----------

EUR: down at USD1.0657 (USD1.0690)

GBP: down at USD1.2479 (USD1.2523)

USD: up at JPY157.87 (JPY157.44)

GOLD: down at USD2,288.56 per ounce (USD2,298.10)

(Brent): down at USD85.48 a barrel (USD86.42)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

China - Labor Day. Financial markets closed.

France - Labor Day. Financial markets closed.

Germany - Labor Day. Financial markets closed.

Ireland - Labor Day. Financial markets closed.

Italy - Labor Day. Financial markets closed.

Spain - Labor Day. Financial markets closed.

Switzerland - Labor Day. Financial markets closed.

09:30 BST UK manufacturing PMI

11:00 BST Ireland unemployment

13:15 BST US ADP jobs report

14:45 BST US manufacturing PMI

15:00 BST US ISM manufacturing PMI

15:00 BST US job openings and labour turnover survey

19:00 BST US interest rate decision

----------

UK house price growth slowed last month, numbers from Nationwide showed. UK house prices rose 0.6% on-year in April, easing from a 1.6% surge in March. On a monthly basis, they fell 0.4%. They had declined 0.2% in March from February. "UK house prices fell by 0.4% in April, after taking account of seasonal effects. This resulted in a slowing in the annual rate of house price growth to 0.6% in April, from 1.6% the previous month," Nationwide analyst Robert Gardner said. "The slowdown likely reflects ongoing affordability pressures, with longer term interest rates rising in recent months, reversing the steep fall seen around the turn of the year. House prices are now around 4% below the all-time highs recorded in the summer of 2022, after taking account of seasonal effects."

----------

Politicians and canvassers are beginning their final day of campaigning ahead of Thursday's local elections in the UK. Voters in England and Wales will go to the polls on May 2 for local, mayoral, and police and crime commissioner elections. The polls are the final test of public opinion at the ballot box ahead of the next general election, which Prime Minister Rishi Sunak has said will come in the second half of 2024. Forecasts suggest the elections could see the Conservatives lose up to half of the council seats they are defending across 107 councils, having lost a third of seats last year. Most of the seats up for re-election were last contested in 2021, at the peak of Boris Johnson's popularity as the Covid-19 vaccine was rolled out. A total of 11 mayoral contests are also taking place, including for the London mayoralty. A wave of defeats for Sunak could be enough to push more Tory MPs into seeking to replace him as leader before the general election, though all counts will not be declared until Sunday, May 5.

----------

BROKER RATING CHANGES

----------

Berenberg raises FirstGroup price target to 195 (191) pence - 'buy'

----------

Berenberg raises HSBC price target to 830 (800) pence - 'buy'

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm GSK said it expects annual sales to rise at the upper end of its forecast, following a "strong" start to 2024. GSK said revenue in the first-quarter of the year rose 5.9% to GBP7.36 billion from GBP6.95 billion a year prior. Pretax profit, however, weakened 29% to GBP1.36 billion from GBP1.91 billion. GSK reported 'other' expenses worth GBP533 million, hurting its bottom line, and swing from GBP297 million in gains a year prior. Chief Executive Officer Emma Walmsley said: "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic areas this quarter: infectious diseases, HIV, respiratory/immunology and oncology. We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024." GSK now expects annual revenue to rise at the upper part of its 5% to 7% range, at constant currency. It expects constant currency operating profit growth in its core operations of 9% to 11%, its outlook raised from 7% to 10%. Core earnings per share growth of 8% to 10% at constant currency is now expected, the guidance bumped up from 6% to 9%.

----------

Haleon, a consumer health arm spun out of GSK, backed its annual guidance and reported a "solid" quarter. Reported revenue declined 2.2% on-year to GBP2.92 billion in the first-quarter of the year. Revenue rose 3.0% on an organic basis, however. Pretax profit grew 8.9% to GBP590 million from GBP542 million. Looking ahead, it still predicts annual organic revenue growth in the 4% to 6% range. CEO Brian McNamara said: "First quarter trading was solid and in line with guidance shared when we reported FY 2023 results. Organic revenue growth of 3.0% was impacted by lapping tough comparatives in the prior year particularly in respiratory health and pain relief." The CEO added: "Regionally, whilst growth was held back in the US from inventory adjustments by some retailers, Haleon's consumption in this region was strong, up mid-single digit and ahead of the market. As such, we remain confident of delivering on our FY guidance."

----------

Retailer Next said sales in recent weeks have been ahead of expectations, and it maintained its annual profit forecast. In the 13 weeks to April 27, its first-quarter, full price sales rose 5.7% on-year. The outcome was ahead of guidance, with the clothing and homewares seller having predicted growth of 5%. It still expects pretax profit to grow 4.6% in the full-year to GBP960 million. Next added: "We are maintaining our guidance for full price sales in the first half to be up 2.5%. This implies that our sales in Q2 will be down -0.3%. We expect the sales performance in the second quarter to be weaker than the first quarter because last year benefited from particularly warm weather from late May through to the end of June."

----------

COMPANIES - FTSE 250

----------

Aston Martin Lagonda recorded weaker results, for a first-quarter that it labelled a "period of transition". The carmaker said revenue in the first-quarter fell 10% to GBP267.7 million from GBP295.9 million a year earlier. Its pretax loss widened to GBP138.8 million from GBP74.2 million. Executive Chair Lawrence Stroll commented: "2024 is a year of immense product transformation at Aston Martin, with the introduction of four new models to the market before the end of the year. Our first quarter performance reflects this expected period of transition, as we ceased production and delivery of our outgoing core models ahead of the ramp up in production of the new Vantage, upgraded DBX707 and our upcoming V12 flagship sports car which we've confirmed today. As part of our ongoing programme of ultra-exclusive models, we will deliver a new Special in the fourth quarter of the year." It expects a second-quarter performance to be "broadly similar" to the first. Stroll added: "In March, we were pleased to successfully complete our planned refinancing, securing improved terms on new five-year senior secured notes. This followed upgrades from leading credit agencies, recognising the significant progress made by Aston Martin over recent years and the opportunity for our strategy to continue to deliver improved performance in the years to come. This, along with our existing lenders demonstrating their continued support through a 70% increase in the new [revolving credit facility] to GBP170 million, marked a significant step in strengthening our balance sheet, aligning Aston Martin for a positive financial future." Net debt as of March 31 stood at GBP1.04 billion, rising 20% from GBP868.1 million a year prior.

----------

Computacenter said its first-quarter went largely in line with expectations, though it noted a "challenging" period in the UK. The technology and IT service provider expects adjusted pretax profit in the first-half to be weaker than the prior year's GBP121.8 million. Computacenter said: "Computacenter expects to make further progress in 2024 with the performance for the group during the first quarter broadly in line with our expectations. Germany and North America delivered solid underlying performances while the UK remained challenging."

----------

OTHER COMPANIES

----------

Luxury brand Mulberry expects to report an annual revenue decline, as it grappled with a "backdrop of challenging macro-economic conditions". Group revenue for the year ended March 30 fell 4%, or 2.7% at constant currency, it said. "While we achieved positive revenue growth in the first half, Mulberry has not been immune to the broader downturn in luxury spending experienced in recent months, particularly in the UK and Asia. This decline was partially offset by positive trading in the US, where we have benefitted from increased brand awareness," CEO Thierry Andretta said. "Looking ahead, the trading environment in the UK and China remains challenging and we do not expect this to change in the short term. We are therefore managing the business prudently, focusing on executing our strategy and vision to become a global sustainable luxury brand."

----------

Renold won a GBP10.6 million deal to produce flexible couplings for the Royal Canadian Navy. "This contract, together with other military work recently awarded, means that Renold's military order book has increased by GBP13.1 million, over recent months," the supplier of industrial chains and related power transmission products said. Renold explained the new pact with be delivered over the next six years. Flexible couplings are a key component on a ship's propulsion system, the firm said.

----------

Touchstone Exploration said it has struck an all-share deal to acquire Trinity Exploration & Production. The all-share agreement values the latter at GBP24.1 million. Touchstone Exploration, oil and natural gas exploration and production active in Trinidad & Tobago, said the deal will create a "leading Trinidadian operator of scale". It said: "The addition of Trinity's existing production portfolio, along with its exploration and development assets, will position the combined group as one of the leading independent operating companies dedicated to investing in both onshore and offshore activity to grow Trinidadian oil and gas production." As part of the deal, Trinity shareholders will receive 1.5 new Touchstone shares for each Trinity share owned. Trinity Shareholders will own just under 20% of the combined firm. Trinity directors consider the terms of the deal to be "fair and reasonable".

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more
4 Jan 2024 14:01

UK dividends calendar - next 7 days

Friday 5 January 
British Land Co PLCdividend payment date
Hill & Smith PLCdividend payment date
JD Sports Fashion PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Liontrust Asset Management PLCdividend payment date
Lok'n Store Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
RS Group PLCdividend payment date
Tate & Lyle PLCdividend payment date
Monday 8 January 
abrdn Equity Income Trust PLCdividend payment date
Intermediate Capital Group PLCdividend payment date
Tuesday 9 January 
no events scheduled 
Wednesday 10 January 
Assura PLCdividend payment date
Bellway PLCdividend payment date
Fidelity Special Values PLCdividend payment date
LXi REIT PLCdividend payment date
Severn Trent PLCdividend payment date
Volex PLCdividend payment date
Vp PLCdividend payment date
Thursday 11 January 
AJ Bell PLCex-dividend payment date
Ashtead Group PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
CMC Markets PLCdividend payment date
dotdigital Group PLCex-dividend payment date
Ecora Resources PLCex-dividend payment date
European Assets Trust PLCex-dividend payment date
Foresight Group Holdings Ltdex-dividend payment date
GSK PLCdividend payment date
ICG-Longbow Senior Secured UK Property Debt Investments Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
Keystone Positive Change Investment Trust PLCex-dividend payment date
LondonMetric Property PLCdividend payment date
Murray International Trust PLCex-dividend payment date
National Grid PLCdividend payment date
Primary Health Properties PLCex-dividend payment date
Sage Group PLCex-dividend payment date
Smiths News PLCex-dividend payment date
SSE PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
TR Property Investment Trust PLCdividend payment date
Walker Crips Group PLCex-dividend payment date
WH Smith PLCex-dividend payment date
Worldwide Healthcare Trust PLCdividend payment date
XPS Pensions Group PLCex-dividend payment date
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.